The effect of tissue plasminogen activator on retinal bleeding.
暂无分享,去创建一个
[1] R. Califf,et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. , 1988, The American journal of medicine.
[2] R. Devenyi,et al. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. , 1988, Archives of ophthalmology.
[3] A. Jaffe,et al. Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .
[4] R. Snyder,et al. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. , 1987, American journal of ophthalmology.
[5] R. Snyder,et al. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model. , 1987, Archives of ophthalmology.
[6] S. Forman,et al. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.
[7] R. Snyder,et al. Use of tissue plasminogen activator in experimental hyphema. , 1987, Archives of ophthalmology.
[8] S. D. Bustros,et al. Thrombin infusion for the control of intraocular bleeding during vitreous surgery. , 1985, Archives of ophthalmology.
[9] A. Schachat,et al. Complications of vitreous surgery for diabetic retinopathy. I. Intraoperative complications. , 1983, Ophthalmology.
[10] Sebestyen Jg. Fibrinoid syndrome: a severe complication of vitrectomy surgery in diabetics. , 1982 .
[11] H. Little. Alterations in blood elements in the pathogenesis of diabetic retinopathy. , 1981, Ophthalmology.